The continuous evaluation of EGFR mutation in EGFR-mutation positive lung cancer patients during EGFR TKI treatment

The continuous evaluation of EGFR mutation in EGFR-mutation positive lung cancer patients during EGFR TKI treatment - The continuous evaluation of EGFR mutation during EGFR TKI treatment

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037232

Enrollment

100

Registered

2019-07-04

Start date

2019-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: non-small cell lung cancer patients carrying EGFR activating mutation

Exclusion criteria

Exclusion criteria: disagreed patients and patients carrying HBV or HCV

Design outcomes

Primary

Measure	Time frame
To evaluate EGFR mutation status during EGFR TKI treatment	—

Secondary

Measure	Time frame
To evaluate the efficacy of EGFR TKI treatment and EGFR mutation status	—

Countries

Japan

Contacts

Public ContactToshimitsu Yamaoka

Showa University Advanced Cancer Translational Research Institute

yamaoka.t@med.showa-u.ac.jp03-3784-8146

Outcome results